Crystalline forms of a Janus kinase inhibitor
The present invention relates to crystalline forms of the Janus kinase (JAK) inhibitor 3-((3S,4R)-3-methyl-6-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile (Compound A), as well as, compositions thereof, methods of their preparation, methods of use thereof and methods of quantitation.
1. A crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4] octan-1-yl)-3-oxopropanenitrile having an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ)(°), at about 11.8.
2. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern comprises one or more additional characteristic peaks, in terms of 2θ(°), selected from about 10.5, about 19.3, and about 22.0.
3. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern comprises two or more additional characteristic peaks, in terms of 2θ(°), selected from about 7.8, about 10.5, about 13.4, about 13.9, about 17.8, about 19.3, about 22.0, about 23.6, and about 28.0.
4. A crystalline form of 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3 0.4] octan-1-yl)-3-oxopropanenitrile having a DSC thermogram which is characterized by an endothermic peak at about 186° C.
5. The crystalline form of any one of claims 1 and 2 to 4 , having a purity of at least about 50%.
6. The crystalline form of any one of claims 1 and 2 to 4 , having a purity of at least about 75%.
7. The crystalline form of any one of claims 1 and 2 to 4 , having a purity of at least about 85%.
8. The crystalline form of any one of claims 1 and 2 to 4 , having a purity of at least about 90%.
9. The crystalline form of any one of claims 1 and 2 to 4 , having a purity of at least about 95%.
10. A composition of crystalline 3-((3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl)-3-oxopropanenitrile comprising Form α and Form β, wherein Form a is characterized as having an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ(°), at about 10.2, and wherein Form (3 is characterized as having an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ(°), at about 11.8.
11. The composition of claim 10 consisting essentially of Form α and Form β.
12. The composition of claim 10 , wherein Form β is present in an amount of about 1 to about 50% w/w with respect to Form α.
13. The composition of claim 10 , wherein Form β is present in an amount of about 1 to about 20% w/w with respect to Form α.
14. The composition of claim 10 , wherein Form β is present in an amount of about 1 to about 10% w/w with respect to Form α.
15. The composition of claim 10 , wherein Form β is present in an amount of about 1 to about 5% w/w with respect to Form α.
16. The composition of claim 10 , further comprising Form γ, wherein Form γ is characterized as having an X-ray powder diffraction pattern comprising two or more peaks, in terms of 2θ(°), selected from about 16.5, about 17.7, about 21.4, about 21.8, and about 23.1.
17. A pharmaceutical composition comprising the crystalline form or composition of any one of claims 1 , 2 to 5 , and 10 to 16 , and a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of claim 17 which is suitable for oral, parenteral, pulmonary, local, or topical administration.
19. The pharmaceutical composition of claim 17 which is suitable for topical administration.
20. The pharmaceutical composition of claim 17 in the form of a tablet, capsule, pill, powder, or ointment.
21. The pharmaceutical composition of claim 17 in the form of a powder suitable for reconstitution in liquid for IV, IM, or SC administration.
22. The pharmaceutical composition of claim 17 , comprising white soft paraffin, hard paraffin, squalene, or a mixture thereof.
23. A method for treating or preventing a disease selected from organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic diseases, and chronic myeloproliferative disease, comprising administering to a mammal a therapeutically effective amount of the crystalline form or composition of any one of claims 1 , 2 to 4 , and 10 to 16 .
24. A method for treating or preventing rheumatoid arthritis, psoriasis, alopecia areata, dry eye, atopic dermatitis, eczema, or hand eczema comprising administering to a mammal a therapeutically effective amount of the crystalline form or composition of any one of claims 1 , 2 to 4 , and 10 to 16 .